Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 (vol 15, pg 429, 2009)

被引：2
|
作者：
Junttila, Teemu T. [1 ]
Akita, Robert W. [1 ]
Parsons, Kathryn [1 ]
Fields, Carter [1 ]
Phillips, Gail D. Lewis [1 ]
Friedman, Lori S. [1 ]
Sampath, Deepak [1 ]
Sliwkowski, Mark X. [1 ]
机构：
[1] Genentech Inc, Res Oncol, San Francisco, CA 94080 USA
来源：
CANCER CELL | 2011年 / 20卷 / 06期
关键词：
D O I：
10.1016/j.ccr.2011.12.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：818 / 818
页数：1
相关论文
共 50 条
  • [21] Mechanism of PI3K activation by the HER3/ErbB3 receptor
    Michael, Nicole
    Hopkins, Michael
    Jura, Natalia
    CANCER RESEARCH, 2016, 76
  • [22] Targeting HER2 and PI3K in Uterine Serous Cancer
    Diver, E. J.
    Hernandez, S. F.
    Scaltriti, M.
    Rueda, B. R.
    Growdon, W. B.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 596 - 596
  • [23] The PI3K inhibitor GDC-0941 is synergistic with lapatinib, and mediates endocrine sensitivity in uterine papillary serous carcinoma
    Levano, Kelly S.
    Rodriguez-Gabin, Alicia
    Goldberg, Gary L.
    Horwitz, Susan B.
    Hou, June Y.
    CANCER RESEARCH, 2014, 74 (19)
  • [24] Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells
    Laterza, M. M.
    Ciaramella, V.
    Morgillo, F.
    Belli, V.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Savastano, B.
    Pappalardo, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
    Balz, Lydia M.
    Bartkowiak, Kai
    Andreas, Antje
    Pantel, Klaus
    Niggemann, Bernd
    Zaenker, Kurt S.
    Brandt, Burkhard H.
    Dittmar, Thomas
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 234 - 244
  • [26] PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
    Chung, Wei-Pang
    Huang, Wei-Lun
    Lee, Chun-Hui
    Hsu, Hui-Ping
    Huang, Wan-Ling
    Liu, You-Yu
    Su, Wu-Chou
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 3067 - +
  • [27] The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination (vol 227, pg 234, 2012)
    Balz, L. M.
    JOURNAL OF PATHOLOGY, 2013, 230 (01): : e1 - e1
  • [28] MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers
    Hoe, Nicholas
    Mateling, Michael
    Ma, Yating
    Jin, Kelly
    Zhou, JinYao
    Kirkland, Richard
    Kuy, Crystal
    Liu, Xinjun
    Kim, Phillip
    Singh, Sharat
    CANCER RESEARCH, 2013, 73 (08)
  • [29] Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC)
    Laterza, M. M.
    Ciaramella, V.
    Morgillo, F.
    Belli, V.
    Tirino, G.
    Pompella, L.
    Petrillo, A.
    Savastano, B.
    Pappalardo, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel PI3K inhibitor GDC-0941
    Salphati, Laurent
    Belvin, Marcia
    Edgar, Kyle
    Prior, Wei Wei
    Sampath, Deepak
    Wallin, Jeffrey
    Wong, Harvey
    DRUG METABOLISM REVIEWS, 2009, 41 : 164 - 164
12345